AXM Pharma Competitors

AXM Pharma (OTCMKTS:AXMP) and Woodbrook Group (OTCMKTS:WDBG) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, risk, dividends, analyst recommendations, institutional ownership, profitability and earnings.

Earnings and Valuation

This table compares AXM Pharma and Woodbrook Group's top-line revenue, earnings per share and valuation.

Risk and Volatility

AXM Pharma has a beta of -52.62, meaning that its share price is 5,362% less volatile than the S&P 500. Comparatively, Woodbrook Group has a beta of -2.24, meaning that its share price is 324% less volatile than the S&P 500.

Analyst Recommendations

This is a summary of recent recommendations and price targets for AXM Pharma and Woodbrook Group, as provided by MarketBeat.com.

Profitability

This table compares AXM Pharma and Woodbrook Group's net margins, return on equity and return on assets.

Summary

Woodbrook Group beats AXM Pharma on 1 of the 1 factors compared between the two stocks.

AXM Pharma (OTCMKTS:AXMP) and Rosetta Genomics (OTCMKTS:ROSGQ) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, valuation, dividends, institutional ownership, risk, earnings and analyst recommendations.

Profitability

This table compares AXM Pharma and Rosetta Genomics' net margins, return on equity and return on assets.

Earnings and Valuation

This table compares AXM Pharma and Rosetta Genomics' revenue, earnings per share (EPS) and valuation.

Analyst Recommendations

This is a summary of current ratings for AXM Pharma and Rosetta Genomics, as reported by MarketBeat.com.

Risk & Volatility

AXM Pharma has a beta of -52.62, meaning that its stock price is 5,362% less volatile than the S&P 500. Comparatively, Rosetta Genomics has a beta of 6.39, meaning that its stock price is 539% more volatile than the S&P 500.

Summary

Rosetta Genomics beats AXM Pharma on 1 of the 1 factors compared between the two stocks.

AXM Pharma (OTCMKTS:AXMP) and PhaseRx (OTCMKTS:PZRXQ) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, dividends, valuation, profitability, risk, analyst recommendations and institutional ownership.

Analyst Recommendations

This is a breakdown of recent ratings and price targets for AXM Pharma and PhaseRx, as provided by MarketBeat.com.

Profitability

This table compares AXM Pharma and PhaseRx's net margins, return on equity and return on assets.

Valuation and Earnings

This table compares AXM Pharma and PhaseRx's revenue, earnings per share and valuation.

Volatility & Risk

AXM Pharma has a beta of -52.62, meaning that its stock price is 5,362% less volatile than the S&P 500. Comparatively, PhaseRx has a beta of -0.86, meaning that its stock price is 186% less volatile than the S&P 500.

Summary

PhaseRx beats AXM Pharma on 1 of the 1 factors compared between the two stocks.

AXM Pharma (OTCMKTS:AXMP) and Orexigen Therapeutics (OTCMKTS:OREXQ) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, risk, profitability, institutional ownership, earnings, analyst recommendations and valuation.

Volatility & Risk

AXM Pharma has a beta of -52.62, suggesting that its share price is 5,362% less volatile than the S&P 500. Comparatively, Orexigen Therapeutics has a beta of 4.98, suggesting that its share price is 398% more volatile than the S&P 500.

Valuation & Earnings

This table compares AXM Pharma and Orexigen Therapeutics' top-line revenue, earnings per share (EPS) and valuation.

AXM Pharma has higher earnings, but lower revenue than Orexigen Therapeutics.

Profitability

This table compares AXM Pharma and Orexigen Therapeutics' net margins, return on equity and return on assets.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for AXM Pharma and Orexigen Therapeutics, as reported by MarketBeat.

Summary

Orexigen Therapeutics beats AXM Pharma on 2 of the 2 factors compared between the two stocks.

MetaStat (OTCMKTS:MTST) and AXM Pharma (OTCMKTS:AXMP) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, profitability, dividends, valuation, risk, earnings and institutional ownership.

Volatility and Risk

MetaStat has a beta of -4.21, suggesting that its stock price is 521% less volatile than the S&P 500. Comparatively, AXM Pharma has a beta of -52.62, suggesting that its stock price is 5,362% less volatile than the S&P 500.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for MetaStat and AXM Pharma, as reported by MarketBeat.

Valuation & Earnings

This table compares MetaStat and AXM Pharma's gross revenue, earnings per share (EPS) and valuation.

AXM Pharma has lower revenue, but higher earnings than MetaStat.

Profitability

This table compares MetaStat and AXM Pharma's net margins, return on equity and return on assets.

Summary

MetaStat beats AXM Pharma on 2 of the 2 factors compared between the two stocks.

AXM Pharma (OTCMKTS:AXMP) and Alseres Pharmaceuticals (OTCMKTS:ALSE) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, valuation, earnings, dividends, institutional ownership, risk and profitability.

Earnings & Valuation

This table compares AXM Pharma and Alseres Pharmaceuticals' revenue, earnings per share (EPS) and valuation.

Volatility and Risk

AXM Pharma has a beta of -52.62, suggesting that its stock price is 5,362% less volatile than the S&P 500. Comparatively, Alseres Pharmaceuticals has a beta of -0.06, suggesting that its stock price is 106% less volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of recent ratings for AXM Pharma and Alseres Pharmaceuticals, as provided by MarketBeat.

Profitability

This table compares AXM Pharma and Alseres Pharmaceuticals' net margins, return on equity and return on assets.

Summary

Alseres Pharmaceuticals beats AXM Pharma on 1 of the 1 factors compared between the two stocks.